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Abstract
The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-
hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal
keratinocytes. Since nuclear factor-kB (NF-kB) plays a pivotal role in the regulation of cell proliferation, differentiation and
apoptosis, we examined the capability of 20-hydroxycholecalciferol to modulate the activity of NF-kB, using 1,25-
dihydroxycholecalciferol (calcitriol) as a positive control. 20-hydroxycholecalciferol inhibits the activation of NFkB DNA
binding activity as well as NF-kB-driven reporter gene activity in keratinocytes. Also, 20-hydroxycholecalciferol induced
significant increases in the mRNA and protein levels of the NF-kB inhibitor protein, IkBa, in a time dependent manner, while
no changes in total NF-kB-p65 mRNA or protein levels were observed. Another measure of NF-kB activity, p65 translocation
from the cytoplasm into the nucleus was also inhibited in extracts of 20-hydroxycholecalciferol treated keratinocytes.
Increased IkBa was concomitantly observed in cytosolic extracts of 20-hydroxycholecalciferol treated keratinocytes, as
determined by immunoblotting and immunofluorescent staining. In keratinocytes lacking vitamin D receptor (VDR), 20-
hydroxycholecalciferol did not affect IkBa mRNA levels, indicating that it requires VDR for its action on NF-kB activity.
Comparison of the effects of calcitrol, hormonally active form of vitamin D3, with 20-hydrocholecalciferol show that both
agents have a similar potency in inhibiting NF-kB. Since NF-kB is a major transcription factor for the induction of
inflammatory mediators, our findings indicate that 20-hydroxycholecalciferol may be an effective therapeutic agent for
inflammatory and hyperproliferative skin diseases.
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Introduction
Human keratinocytes have the ability to metabolize vitamin D3
autonomously [1,2,3]. Not only are they the site of conversion of
7-dehydrocholesterol (7DHC) to vitamin D3 following UVB-
radiation [2,4,5], but they also express enzymes to hydroxylate
vitamin D3 to the hormonally active form known as calcitriol or
1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Thus, keratinocytes
are the site of production and the target for vitamin D3 [3]. We
have recently identified new pathway for metabolism of vitamin D
and pro-vitamin D that is catalyzed by cytochrome P450scc
(CYP11A1) [6,7,8,9,10,11,12], the enzyme catalyzing the conver-
sion of cholesterol to pregnenolone for steroid hormone synthesis
[13]. 20-Hydroxyvitamin D3 (20(OH)D3) is the major product of
P450scc activation of vitamin D3 as well as an intermediate in the
sequential synthesis of other hydroxylated derivatives including
20,23-dihydroxyvitamin D3 (20,23(OH)2D3 and 17,20,23-trihy-
droxyvitamin D3 (17,20,23(OH)3D3) (see Figure 1) [7,10,11]. We
postulated that 20(OH)D3 could have systemic effects when
produced in organs expressing high levels of P450scc, such as
adrenal cortex, corpus luteum, follicles and placenta [7,14], while
in organs expressing low levels of P450scc, such as skin [8],
20(OH)D3 could serve local paracrine, autocrine or intracrine
roles. In fact, we have recently demonstrated that 20(OH)D3 can
stimulate differentiation and inhibit proliferation of keratinocyte
cultured in vitro [15].
Vitamin D3 has a wide variety of actions in autoimmune
diseases and cancer [16,17,18,19,20] as well as on bone physiology
and blood pressure [21,22,23]. The biological role of its metabolite
20(OH)D3 is only partially known [15], while it is well
documented that 1,25(OH)2D3 and its derivatives [24] have
diverse biological activities on multiple cell lineages
[2,21,25,26,27], including modulation of the skin immune system
(SIS) and protection of the skin against UVB-induced damage
[25,26,28,29,30,31,32].
Inflammation and proliferation are regulated by a plethora of
transcription factors, with nuclear factor-kB (NF-kB) considered to
be a master regulator of these processes (reviewed in [33]). NF-kBi s
also important in the development, prevention and therapy of
cancer [34,35,36]. NF-kB activity is stimulated by many pathways
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activated by various cytokines, such as the proinflammatory
cytokine IL-1 (reviewed in [37,38]), lipopolysaccharide (LPS) and
tumor necrosis factor a (TNF-a) [39,40]. In mammals, the NF-kB
family of proteins includes NF-kB1 (p105 processed to p50), NF-
kB2 (p100 processed to p52), RelA (p65), RelB and cRel [41].
Phosphorylation and subsequent degradation of IkB proteins allow
for translocation of cytoplasmic NF-kB into the nucleus, where NF-
kB binds to specific promoter/enhancer elements to regulate the
expression of specific genes [33]. NF-kB regulated genes play
important roles in inflammation, immunity, cell growth and cell
survival [42,43,44,45].
NF-kB activation is mediated through the activation of specific
IkB kinases (IKKs) and the subsequent phosphorylationof IkB. The
pathway leading to proteolysis of IkB is denoted as the canonical
NF-kB activation pathway. NF-kB activation also occurs through
the ‘noncanonical’ pathway, which does not involve IkB degrada-
tion and is activated by various agents, including interferon-a/b,
lipopolysaccharide, the LMP1 protein of Epstein-Barr virus, B-cell
activating factor and lymphotoxin-b [42,46].
Vitamin D and various synthetic vitamin D analogues have
been widely used in the treatment of psoriasis [47] and other
inflammatory/hyperproliferative skin disorders [48,49]. The
cellular actions of 1,25(OH)2D3, the bioactive form of vitamin
D, are not fully understood, but its effects have traditionally been
ascribed to its binding to the vitamin D receptor (VDR)
[50,51,52,53]. NF-kB plays an important role in protecting
keratinocytes against apoptosis during programmed cornification
[54]. In normal human keratinocytes, 1,25(OH)2D3 reduces NF-
kB DNA binding activity by increasing IkBa protein levels, which
inhibits IL-8 production [55]. A similar effect is also seen in
murine macrophages [56,57]. Effects of 1,25(OH)2D3 on NF-kB
that are not mediated by the VDR have also been reported for
fibroblasts lacking the VDR [58].
In the present study we have examined the effects of 20(OH)D3
on NF-kB signaling in comparison to well defined effects of
1,25(OH)2D3. Since NF-kB dysregulation induces malignant
transformation of HaCaT keratinocytes, but not of normal
keratinocytes [59], we used in these studies both immortalized
human HaCaT keratinocytes and primary epidermal keratinocytes,
isolated from human neonatal foreskin (HEKn). The effects of
1,25(OH)2D3 on both expression of genes involved in its
metabolism and the biological activity of the encoded proteins
have previously been studied in these cells [26,60]. Recent data
from our laboratories indicates that 20(OH)D3 can be produced by
adrenalmitochondria[7],thatadrenalglandsex-vivocantransform
7DHC to 5,7-diene products [61] that in the skin can be converted
tobiologicallyactivevitaminD-likeproducts[62].Therefore,action
of 20(OH)D3 on NF-kB activity would suggest a role for a novel
endogenous secosteroidogenic metabolic pathway [7,8,9,10,11] in
the regulation of the systemic and cutaneous immune activity.
Results
20-Hydroxycholecalciferol inhibits NF-kB DNA binding
activity in keratinocytes
In initial experiments we determined that 20(OH)D3 at 100 nM
was optimal for inducing biological actions like stimulation of
keratinocytes differentiation and inhibition of cell proliferation [15].
Next we examined the effect of 20(OH)D3 on NF-kB activity in
keratinocytes by assaying nuclear extracts of 20(OH)D3-stimulated
cells by DNA-binding assays. Primary human keratinocytes and
HaCaT cells were incubated with 100 nM 20(OH)D3, nuclear
extracts were prepared and incubated with an NF-kB oligonucle-
otide probe based on the kB binding site in the immunoglobulin
light chain enhancer. As shown in figure 2A and 2C, a time
dependent decrease in nuclear protein binding to the kB response
element was observed in extracts from 20(OH)D3-treated cells.
Inhibition of NF-kB activity was observed within 30 minutes of
20(OH)D3 addition. Maximum inhibition was reached by 4 hours,
and inhibition persisted up to 24 hours. This effect was no longer
observed after 48 hours. Treatment with 1,25(OH)2D3 also had
similar inhibitory effect of NF-kB activity (data not shown). High
basal NF-kB activity in HaCaT cells is probably due to serum
deprivation of cells, since previously we have demonstrated that
serum deprivation triggers NF-kB activation in HaCaT cells [63].
Figure 1. P450scc (CYP11A1) can hydroxylate vitamin D3 to 20-hydroxycholecalciferol with following sequential metabolism to
other hydroxyderivatives [10].
doi:10.1371/journal.pone.0005988.g001
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NF-kB complexes, nuclear extracts were preincubated with
antibodies against the p65 and p50 NF-kB proteins and analyzed
by supershift assays. As shown in figure 2B and 2D, the
20(OH)D3-induced complex contains both p50 and p65 proteins.
The specificity of the binding to the kB probe was determined by
incubating nuclear extract with excess unlabeled (cold) NF-kB
oligonucleotide. Since excess unlabeled NF-kB oligonucleotide
competed out DNA binding to the kB probe, NF-kB binding was
considered specific.
20-Hydroxycholecalciferol inhibits NFkB-driven reporter
gene activity in keratinocytes
In order to determine functional consequences of the decreased
NF-kB DNA binding activity in the keratinocytes treated with
20(OH)D3, we performed gene reporter assays to determine NF-
kB driven transcriptional activity (Fig. 3). HaCaT and normal
human keratinocytes were transiently transfected with the pNFkB-
Luc construct, which contained the firefly luciferase reporter gene
driven by NF-kB. In the presence of 1,25(OH)2D3 or 20(OH)D3,
basal luciferase activity decreased (Fig. 3). The inhibitory effect
was more pronounced in normal human keratinocytes, with
approximately a 2.5-fold decrease in the reporter activity (p,0.01)
(Fig. 3A). In immortalized keratinocytes (HaCaT) the decrease in
activity was less pronounced, but was also statistically significant
(p,0.05) (Fig. 3A). 20(OH)D3 and 1,25(OH)2D3 had similar
potency in inhibiting the NF-kB driven reporter in keratinocytes.
Interestingly, NF-kB activity was significantly inhibited even after
24 hours of treatment with either agent (Fig. 3A).
To further characterize the inhibitory activity of 20(OH)D3 and
1,25(OH)2D3, NF-kB activity in HaCaT and normal human
keratinocytes was stimulated by two agents known to induce NF-
kB activity, LPS or IL-1a. As shown in Figure 3B, both LPS and
IL-1a increased NF-kB-driven luciferase activity in HaCaT cells
and normal human keratinocytes, as compared to cells treated
with vehicle (,0.01% ethanol). We next examined the effects of
20(OH)D3 or 1,25(OH)2D3 on luciferase activity in HaCaT cells
stimulated with LPS or IL-1a. Treatment with 20(OH)D3 or
1,25(OH)2D3 resulted in a statistically significant (p,0.05)
decrease in NF-kB-driven luciferase expression in HaCaT cells
stimulated by LPS or IL-1a with 20(OH)D3 and 1,25(OH)2D3
exhibiting similar potencies in inhibiting NF-kB activity. We than
analyzed luciferase activity in cell extracts from human epidermal
keratinocytes (HEKn), treated with 20(OH)D3 or 1,25(OH)2D3
and stimulated with LPS or IL-1a. Interestingly, the inhibition by
20(OH)D3 or 1,25(OH)2D3 of NF-kB activity was greater when
the keratinocytes were stimulated with LPS as compared to IL-1a.
20(OH)D3 was slightly less potent in inhibiting NF-kB activity in
keratinocytes when compared to 1,25(OH)2D3. Thus, despite the
cell-type differences in the stimulation of NF-kB-dependent
transcription activity by LPS versus IL-1a, 20(OH)D3 and
1,25(OH)2D3 inhibited NF-kB-dependent transcription.
20-Hydroxycholecalciferol inhibits translocation of the
p65 NFkB protein induced by IL-1a in keratinocytes
To further characterize the inhibitory effect of 20(OH)D3 on
NF-kB activity, we examined the cellular localization of the p65
NF-kB protein and the IkBa inhibitory protein in keratinocytes
Figure 2. 20(OH)D3 treatment inhibits the activation of NFkB DNA binding activity in keratinocytes. Nuclear extracts were prepared
from human keratinocytes, normal and HaCaT, treated with 100 nM 20(OH)D3 for indicated time periods, and were subjected to EMSA (A,C). Nuclear
extracts were preincubated with NF-kB antibodies (p65 and p50) and subjected to supershift assay (B,D). ‘‘Cold’’ represents nuclear extract
preincubated with an excess of unlabelled oligonucleotide.
doi:10.1371/journal.pone.0005988.g002
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lated cells, NF-kB is localized mainly in the cytoplasm with only
minor nuclear staining detected. Stimulation of cells by IL-1a
induced p65 translocation from the cytoplasm into the nucleus,
indicative of the NF-kB activation. In contrast, treatment of cells
with 20(OH)D3 nearly completely blocked the nuclear translo-
cation of p65. In addition, there was a detectable increase in
IkBa protein localized in the cytoplasm after treatment with
20(OH)D3 in comparison to vehicle-treated cells (Fig. 4). Similar
results were obtained when HaCaT and normal keratinocytes
Figure 3. 20(OH)D3 treatment inhibits the activation of NFkB-dependant activity in keratinocytes. Keratinocytes were transiently
transfected with a NFkB-Luc construct for 24 h then treated with 100 nM 20(OH)D3, 1,25(OH)2D3 or ethanol as a vehicle for the indicated time
periods (A), or additionally stimulated with LPS (1 mg/ml) or IL-1a (10 ng/ml) for 30 min (B and C, respectively). Cell lysates prepared from HaCaT and
normal human keratinocytes were assayed for luciferase activity. The data from six experiments performed in quadruplicate are presented as
means6STDEV. *p,0.05 and **p,0.01 between control (non treated cells) and treated cells.
doi:10.1371/journal.pone.0005988.g003
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shown).
20-hydroxycholecalciferol increases IkBa protein levels in
keratinocytes
Since we demonstrated by various assays (EMSA, gene reporter
assays, and immunofluorescence assays) that 20(OH)D3 inhibits
NF-kB activity, we next examined the underlying mechanism
responsible for this activity. In the classical NF-kB pathway, NF-
kB activity is sequestered it in the cytoplasm by forming a complex
with inhibitory IkB proteins. Moreover, as shown in figure 4
20(OH)D3 appears to increase cellular IkB levels as determined by
immunofluorescent staining. To determine whether 20(OH)D3
affects the classical NF-kB pathway, the cellular levels of IkBa and
the p65 NFkB were determined at various times after 20(OH)D3
addition to cells. 20(OH)D3 induced a time-dependent increase in
IkBa levels in whole cell extracts of HEKn (Fig. 5A) and HaCaT
keratinocytes (Fig. 5C). IkBa was increased within 1 hour of
20(OH)D3 treatment, and by 16 hours IkBa was diminished to
the levels observed in untreated cells. Similar results were obtained
when cells were treated with 1,25(OH)2D3. In contrast, cellular
levels of p65 was unaffected by 20(OH)D3 treatment of
keratinocytes. As shown figure 5B and 5D, statistically significant
changes were observed for IkBa levels induced by 20(OH)D3 and
1,25(OH)2D3 expressed relative to b-actin (p,0.05).
To further characterize the ability of 20(OH)D3 to inhibit NF-
kB activity we stimulated NF-kB activity in normal human
keratinocytes with IL-1a and determined IkBa levels in cytosolic
extracts. We found that the concentration of IkBa levels were
increased after treatment with 20(OH)D3 for 1 and 4 hours
(Fig. 6A). Treatment of cells with 20(OH)D3 without IL-1a
stimulation had a similar effect on IkBa levels. As shown figure 6B,
statistically significant changes were observed for IkBa levels
induced by 20(OH)D3 expressed relative to b-actin (p,0.05).
20-Hydroxycholecalciferol stimulates IkBa mRNA
expression, but does not affect NF- kB mRNA expression
in keratinocytes
To determine whether the increased IkBa protein levels in cells
treated with 20(OH)D3 resulting from increased IkBa mRNA
expression, we measured IkB mRNA levels by quantitative real
time PCR (qPCR). As shown in figure 7 the IkBa-mRNA levels
were significantly increased after 20(OH)D3 treatment of HaCaT
and normal human keratinocytes. The induction by 20(OH)D3 of
IkBa mRNA expression was greater in HaCaT cells than in
normal keratinocytes. The effect was already detected 1 hour after
treatment and returned to basal levels by 24 hours in normal
keratinocytes, while the induction of IkBa mRNA persisted up to
24 hours in HaCaT cells. Moreover, the effects of 1,25(OH)2D3
on IkBa mRNA levels were qualitatively similar to those noted for
20(OH)D3. In contrast, mRNA levels of the p50 and p65 NF-kB
subunits were unaffected by treatment with either 1,25(OH)2D3 or
20OHD3 (data not shown).
20-hydroxycholecalciferol requires VDR expression for its
action on the NF-kB pathway in keratinocytes
We previously demonstrated that the action of 20(OH)D3 on
human keratinocytes is dependent on VDR expression [15].
Therefore, we examined whether the effect of 20(OH)D3 on the
NF-kB pathway was also VDR-dependent. Human keratinocytes
were transiently transfected with siRNA to knock-down VDR
expression, treated with 20(OH)D3 or vehicle (ethanol) and
RNA isolated for gene expression analysis by qPCR In parallel
experiments cell extracts were analyzed for protein expression by
western blot. As shown in figure 8A transfection of keratinocytes
with VDR siRNA knocked-down the levels of the vitamin D
receptor by approximately ,80%. Most importantly, knock-
down of the VDR in keratinocytes completely blocked IkBa
mRNA induction by 20(OH)D3 treatment. In contrast,
Figure 4. 20(OH)D3 inhibits the translocation of NFkB-p65 complex into the nucleus and increases the expression of IkBa in the
cytosol of keratinocytes. Primary human keratinocytes, third passage, were incubated for 4 h in KBM medium containing KGF with 100 nM
20(OH)D3 or ethanol vehicle, stimulated with IL-1a for 30 min and then fixed. Cells were stained with anti IkBa or NFkB-p65 antibody, followed by
secondary antibody linked to FITC. Nuclei were stained red with propidium iodide. Cells were analyzed using fluorescent microscope at 406
magnification.
doi:10.1371/journal.pone.0005988.g004
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mRNA in cells transfected with scrambled siRNA (Fig. 8B). The
mRNA levels for p50 and p65 NF-kB proteins were unaffected
by VDR knockdown (data not shown for p50). To further test
the ability of VDR knockdown on NFkB translocation, we
transfected cells with scrambled or VDR siRNA and treated
them with 20(OH)D3, and than examined the cellular
localization of the p65 NF-kB protein and the IkBa inhibitory
protein in keratinocytes by fluorescent microscopy. In summary,
significantly less IkBa protein was localized in the cytoplasm
after 20(OH)D3 treatment of VDR knockdown cells as
compared with scrambled siRNA-treansfected cells (Fig. 8D).
20(OH)D3 treatment of cells nearly completely blocked the
nuclear translocation of p65. In contrast, 20(OH)D3 treatment
Figure 5. 20(OH)D3 increases IkBa protein concentration in keratinocytes and has no effect on NFkB-p65. Keratinocytes, HEKn and
HaCaT were stimulated for the indicated times with 100 nM 20(OH)D3, and 100 nM 1,25(OH)2D3 (HEKn keratinocytes). Cells were lysed, whole cell
extracts prepared, and equivalent amounts of protein were loaded onto polyacrylamide gels. Membranes were incubated with either anti-IkBa, anti-
NFkB-p65 or anti b-actin (internal control) (A, C). Protein concentration expressed relative to b-actin was significantly different to the zero-time
control for IkBa (p,0.05)(B, D). Results from three separate experiments are expressed as mean6STDEV.
doi:10.1371/journal.pone.0005988.g005
Figure 6. 20(OH)D3 increases IkBa protein concentration in cytosolic extracts in keratinocytes. Normal keratinocytes were treated with
100 nM 20(OH)D3 for 1 h and 4 h and then stimulated with or without IL-1a (10 ng/ml) for 30 min. Cells were lysed in lysis buffer and cytosolic
extracts prepared. An equal amount of proteins was loaded onto the polyacrylamide gel. Membranes were incubated with antibodies: anti-IkBa and
anti b-actin (internal control) (A). Protein concentration expressed relative to the concentration of b-actin is shown in (B). Results are expressed as
mean6STDEV.
doi:10.1371/journal.pone.0005988.g006
20OHD3 Decreases NF-kB
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5988of VDR knockdown cells did not block the nuclear translocation
of p65 (Figure 8E).
Discussion
We have previously shown that 20(OH)D3 is a product of
vitamin D3 metabolism by cytochrome P450scc (see Fig. 1) [7,10].
Moreover, 20(OH)D3 has significant biological activity in human
keratinocytes, as it inhibits their proliferation and stimulates their
differentiation [15]. In the present study we demonstrate that
20(OH)D3 is a potent inhibitor of NF-kB activity. Moreover,
20(OH)D3 treatment also increases IkBa protein levels through
induction of IkBa mRNA expression. IkBa induction by
20(OH)D3 requires VDR expression, indicating that 20(OH)D3
acts through the classical vitamin D and NFkB regulatory
pathways.
The inhibitory effect of 20(OH)D3 on NF-kB activity in
keratinocytes was shown by several complementary approaches
including NF-kB dependent DNA binding assays, NFkB-driven
reporter gene activity assays, as well as western blotting and
immunofluorescence analysis of the translocation of p65 NF-kB
subunit from cytoplasm into the nucleus. The inhibitory effect of
20(OH)D3 was rapid (within 30 minutes), reached a maximum by
4 hr after addition, and remained detectable as long as 24 hr after
addition. The inhibitory effect of 20(OH)D3 on NF-kB-dependent
transcriptional activity by luciferase reporter-gene analysis (Fig. 3)
paralleled the time course of 20(OH)D3 inhibition of NF-kB-
dependent DNA binding activity by EMSA (Fig. 2). The inhibitory
effect of 20(OH)D3 on NF-kB was greater in normal human
keratinocytes as compared to the effect in HaCaT keratinocytes.
This discrepancy might be secondary to the immortalization of
HaCaT cells, which might render them less sensitive to 20(OH)D3
treatment. Moreover, 20(OH)D3 had similar potency to that of
the well characterized 1,25(OH)2D3 in inhibiting NF-kB activity
in keratinocytes (no statistically significant difference). The vitamin
D analogs, 1,25(OH)2D3 and 1,24(OH)2D3, have been previously
reported to inhibit NF-kB activity [57]. Also, 1,25(OH)2D3 has
been previously shown to regulate NF-kB DNA binding activity in
human keratinocytes through an increase in IkBa expression [55].
In this study, 1,25(OH)2D3 inhibited NF-kB binding to the IL-8
kB binding sequence more potently than binding to the p53 kB
binding sequence. This selectivity may be mediated through an
increased IkBa expression, indicating that vitamin D analogues
may exert their immunomodulatory effects through NF-kB
regulated proinflammatory cytokines and chemokines. In our
study we tested the effect of the novel analog of vitamin D3,
20(OH)D3, not only on NF-kB activity, but also on protein and
mRNA levels, as well as the role of VDR in the effect of
20(OH)D3 on NF-kB. We clearly demonstrate that 20(OH)D3
inhibits NF-kB activity with potency similar to that of calcitriol
(1,25(OH)2D3, the endogenous active form of vitamin D3). The
mechanism of action or 20(OH)D3 appears to be very similar to
that of 1,25(OH)2D3. The hydroxyl group of 20(OH)D3 is
attached at the C20 position [7]; which is interesting since the
attachment at C1 is considered to be required for full biological
activity and calcemic effects [2,5].
To further characterize the action of 20(OH)D3 on inhibiting
NF-kB activity we used known stimulators of the NF-kB pathway,
LPS and IL-1a [64]. Keratinocytes can produce a plethora of
cytokines including interleukin (IL)-1 and tumor necrosis factor a
(TNF) (reviewed in [37]). IL-1 activates keratinocytes and
promotes their proliferation and migration. Also, LPS is
considered as a potent NF-kB stimulator [65]. In the present
study, 20(OH)D3 was found to attenuate NF-kB transcriptional
activity induced by both LPS or IL-1 in HaCaT cells and primary
keratinocytes, and exhibited a similar potency to 1,25(OH)2D3.
Interestingly, in normal keratinocytes the inhibition of NF-kB
activity stimulated with IL-1a by vitamin D3 hydroxyderivatives
was less pronounced then the inhibition of activity stimulated with
LPS. This indicates that immortalization changes the responsive-
ness of keratinocytes to various stimuli, as it has been
demonstrated in case of neuropeptides [63,66]. Nonetheless, both
20(OH)D3 and 1,25(OH)2D3 inhibit NF-kB activity in keratino-
cytes induced by recognized proinflammatory stimuli.
Figure 7. 20(OH)D3 increases mRNA levels of IkBa in keratinocytes. HEKn and HaCaT keratinocytes were treated with 100 nM 20(OH)D3 or
1,25(OH)2D3 or vehicle for the indicated period of time. Cells were then lysed and total RNA extracted. mRNA levels for IkBa were measured using
reagents for RTPCR according to the manufacturer’s protocol (Roche Applied Science, Manheim, Germany) and normalized relative to Cyclophylin B
RNA. Data are presented as mean6STD (n=3) *p,0.05 versus control, or **p,0.01 versus control. Time response in the expression of mRNA was
shown for NFkBI (IkBa) in both cells.
doi:10.1371/journal.pone.0005988.g007
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the action of 20(OH)D3 on NF-kB activity, since 20(OH)D3
treatment of cells with or without exogenous stimulation had
similar effects on p65 localization and IkBa levels. Although NF-
kB can be activated through both classical and alternative
signaling pathways, previous studies have indicated that IL-1
and LPS activate NF-kB through the classical signaling pathway
[46]. In this general pathway, p50:p65 dimers are sequestered in
the cytoplasm by IkB proteins. LPS and IL-1 stimulate IkB kinase
activity, resulting in the subsequent IkB phosphorylation and
ubiquitinylation. Then IkB is targeted for proteosomal degrada-
tion, which allows p50:p65 dimers to translocate to the nucleus,
bind to DNA and activate the transcription of NF-kB-dependent
genes. Consistent with this general pathway we show that both
LPS and IL-1 stimulate NF-kB transcriptional activity as well as
result in IkB degradation. Most importantly, we show that
20(OH)D3 acts as an immunosuppressive agent in human
keratinocytes by blocking the activation of this signaling pathway
by both IL-1 and LPS. 20(OH)D3 not only inhibits the
translocation of the p65 NF-kB protein from cytoplasm to nucleus
in keratinocytes, but also increases the cellular levels of the
inhibitory NF-kB protein, IkB, thus sequestering the NF-kB in the
cytoplasm as transcriptionally inactive NF-kB/IkB complexes.
Since recent studies demonstrate that activation of the alternative
NF-kB pathway can also lead to the translocation of p65-
containing dimers into the nucleus [42], our data cannot exclude
the possibility that 20(OH)D3 also blocks this signaling pathway as
well. Detailed analysis of the alternative signaling pathway will be
the subject of future studies.
In previous studies we showed that the action of 20(OH)D3 on
proliferation and differentiation in keratinocytes requires VDR
expression [15]. In the present study we find that silencing VDR
expression in keratinocytes blocks the inhibitory actions of
20(OH)D3 on NF-kB activity (Fig. 8). Therefore, our data
indicates that both 20(OH)D3 (novel ligand) and 1,25(OH)2D3
(classical ligand) suppress NF-kB activity through a VDR-
mediated signaling pathway. Although the mechanism of this
pathway in inhibiting NF-kB activity requires more in-depth
analysis, our studies demonstrate that 20(OH)D3 can induce anti-
inflammatory actions similar to those mediated by calcitriol
(1,25(OH)2D3) via the VDR-mediated inhibition of NF-kB
activity. Interestingly vitamin D analogues are now widely used
Figure 8. Silencing of the VDR in human keratinocytes attenuates the effects of 20(OH)D3 on IkBa or NFkB p65 (RelA) expression
and intracellular transolaction. Keratinocytes were transfected with 2 nM scrambled or VDR siRNA and incubated with 100 nM 20(OH)D3 or
vehicle (ethanol) for 4 h. Cells were lysed after treatment and total RNA extracted. VDR mRNA (A), IkBa mRNA (B) and NFkB p65 (RelA) (C) levels were
measured using reagents for RTPCR according to manufacturer’s protocol (Roche Applied Science, Manheim, Germany) and normalized relative to
Cyclophylin B RNA. Data are presented as mean6STD (n=3) *p,0.05 versus control, or **p,0.01 versus control. Levels of VDR and b-actin were
assessed 24 h after transfection with VDR or scrambled siRNA, by western blotting of whole-cell extracts (A). 24 h after transfection with 2 nM
scrambled or VDR siRNA, primary human keratinocytes were also incubated for 4 h in KBM medium containing KGF with 100 nM 20(OH)D3 or
ethanol (vehicle), then fixed. Cells were stained with anti-IkBa antibody (green), followed by secondary antibody linked to FITC. Nuclei were stained
red with propidium iodide (D). Another set of cells was stained with anti-p65 (green) (E). Cells were analyzed using a fluorescent microscope at 206
magnification.
doi:10.1371/journal.pone.0005988.g008
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hyperproliferative dermatoses (reviewed in [49]). Therefore, we
believe that 20(OH)D3 holds promise as a novel therapeutic agent
in the prevention and therapy of inflammatory, auto-immune and
hyperproliferative skin diseases.
Recently, new and important immunomodulatory effects of
vitamin D analogs have been characterized, especially those for
1,25(OH)2D3 [1,25,67]. Inhibitors targeting the NF-kB signaling
pathway effectively suppress NF-kB activity, protect and relieve
inflammatory symptoms, and induce apoptosis of tumor cells. NF-
kB represents an attractive drug target for therapy of inflamma-
tory and autoimmune disorders, as well as for cancer. Thus,
20(OH)D3 is a new powerful analog of vitamin D3 that is
produced by enzymatic activity of CYP11A1 [7,10], and have
pleiotropic activities through its ability to modulate the NF-kB
signaling pathway as illustrated in figure 9. Increased expression of
IkBa and inhibition of NF-kB activity in keratinocytes induced by
20(OH)D3 may be one mechanism by which this (potentially
endogenous) vitamin D analog could exert beneficial effects in
inflammatory and auto-immune disorders.
Materials and Methods
Cell culture
Immortalized human keratinocytes (HaCaT), which are fre-
quently used for studies on biological effect of 1,25(OH)2D3
[30,68], were cultured in Dulbecco’s Modified Eagle Medium
supplemented with glucose, L-glutamine, pyridoxine hydrochlo-
ride (Cell Grow), 5% fetal bovine serum (Sigma) and 1%
penicillin/streptomycin/amphotericin antibiotic solution (Sigma)
[6]. In order to eliminate potential interference by sterols present
in the serum [69], 5% charcoal/dextran-treated bovine serum
(HyClone) was used to test the effects of active forms of vitamin D.
In addition, cells were serum-deprived for 24 h before treatment.
Normal human epidermal keratinocytes were isolated from
neonatal foreskin (HEKn) and grown in KGM medium supple-
mented with KGF (Lonza) on collagen-coated plates [15]. For
experiments cells in their third passage were used.
Immunofluorescent staining
HEKn cells were seeded onto cover glasses in 6-well plate and
treated with 100 nM of 20(OH)D3 for 24 h. Control cells were
treated with solvent (,0.1% ethanol). After treatment cells were
washed in PBS and fixed in 4% paraformaldehyde. Cells were
than incubated in permeabilizing solution (0.2% Triton-X 100 in
PBS) for 5 min, washed with PBS and blocked in 2% BSA for
30 min. Primary antibody, either goat anti-rabbit-p65 (1:100) or
goat anti-rabbit-IkB (1:100) in 1% BSA, was added to the cells and
incubated overnight at 4uC. After extensive washing in PBS, cells
were incubated in the secondary antibody solution comprising
goat-anti-rabbit-Alexa Fluor 488 (Invitrogen, 1:500 in PBS) and
incubated for 1 h at room temperature in the dark. Cells on cover
glass were washed and mounted with mounting medium
containing propidium iodine (Vectashield). Stained cells were
analyzed using a fluorescent microscope at 406magnification.
Transfection and Reporter assay
The constructs pLuc, pHRLTK and NFkB-Luc have been
described previously [70]. According to our protocols [63,66],
HaCaT and normal epidermal keratinocytes were transfected
using Lipofectamine Plus (Invitrogen, Carlsbad, CA) in DMEM or
Figure 9. A schematic representation of the effects of 20(OH)D3 on NFkB signal transduction in keratinocytes.
doi:10.1371/journal.pone.0005988.g009
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with phRL-TK (expresses Renilla luciferase and serves as
normalization control; Promega, Madison, WI). At 24 hr after
transfection, the medium was changed and the cells were treated
with the vitamin D3 derivatives or vehicle (,0.1% ethanol) for 0.5,
1, 4, 16 and 24 h. Following this protocol, cells were also treated
with 10 ng/ml interleukin 1a (IL-1a) (Sigma) or 1 mg/ml LPS
(Sigma) for 30 minutes. The Firefly luciferase and Renilla
luciferase signals were recorded with a TD-20/20 luminometer
(Turner Designs, Sunnyvale, CA); background luminescence was
subtracted and the resulting promoter specific firefly signal was
divided by the Renilla signal (proportional to the number of
transfected cells). The values obtained were calculated relative to
control (untreated) cells, and expressed as relative fold change.
siRNA transfection
Keratinocytes were transfected with 2 nM VDR or scrambled
siRNA (Dharmacon), on-Target plus smart pool human VDR or
on-Target plus siControl non-targeting pool, using lipofectamine
plus (Invitrogen) in DMEM medium. Twenty four hours after
transfection, cells were treated for an additional 4 h with 100 nM
20(OH)D3 or vehicle (ethanol), mRNA was isolated and used for
gene expression analysis or cells were stained for IkBa or NFkB
p65 and examined for protein localization by fluorescent
microscopy.
Preparation of cell lysates
Cells were treated with 20(OH)D3 or 1,25(OH)2D3, and whole
cell lysates were prepared as described previously [71,72]. Cells
were resuspended in RIPA buffer containing protease inhibitor
cocktail (Sigma) and PMSF. Nuclear extracts were prepared as
described previously [73]. In brief, HaCaT or normal human
keratinocytes were treated with 100 nM 20(OH)D3 for 0, 0.5, 1, 4,
16 or 24 h, and then stimulated with or without interleukin 1a
(10 ng/ml) for an additional 30 min. The cells were harvested,
pelleted and resuspended in STM buffer (20 mM Tris-HCl,
250 mM sucrose and 1.1 mM MgCl2). The nuclear pellet was
resuspended in 30 ml nuclear extraction buffer containing 0.4 M
KCl, 5 mM 2-mercaptoethanol and protease inhibitor cocktail
(1:100 dilution, Sigma) in STM buffer, and incubated on ice for
30 min with intermittent shaking and then centrifuged at
14,0006g for 20 min at 4uC. The protein content in the
supernatant was quantified using the Bradford protein assay kit
[74]. Cytosolic extracts were prepared as described previously with
minor modifications [55]. Cell pellets were resuspended in
hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl,
0.2 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5% NP40,
protease inhibitor cocktail (Sigma) and 20 mM PMSF), and after a
20 min of incubation on ice the suspension was centrifuged at 4uC
for 10 minutes at 5,0006g. The centrifuged supernatant was
considered the cytosolic extract.
The levels of IkBa, the p65 NF-kB protein, and b-actin were
assessed by immunoblotting. Primary antibodies used were the
rabbit polyclonal antibodies directed against IkB-a (Santa Cruz,
1:500 dilution); p65 (Santa Cruz, 1:500 dilution) and b-actin-
peroxidase (Sigma, 1:5000 dilution). The secondary antibody used
was anti rabbit IgG (Santa Cruz, 1:7,000 dilution) and anti-mouse
IgG (Santa Cruz, 1:5,000) conjugated to horseradish peroxidase.
Signals were detected using ECL kit Supersignal West Pico
Chemiluminescent Substrate (Pierce). The intensity of bands was
measured using ImageJ Software. Results for whole cell and
cytosolic protein levels were expressed relative to b-actin levels
[74]. Levels of VDR and b-actin 24 h after VDR siRNA
transfection were assessed in western blots with (VDR(D-6))
antibody (Santa Cruz, 1:400).
Electrophoretic mobility shift assay (EMSA)
DNA binding activity was determined by EMSA using a
consensus NF-kB IRDye-labeled oligonucleotide probe (LI-COR).
The DNA binding reaction consisted of 2.5 to 5 mg of the nuclear
extract, the NF-kB probe and gel shift binding buffer containing of
2.5 mM DTT, 0.25% Tween-20 and 0.25 mg/ml poly(dI)
:poly(dC). The reaction was carried out at room temperature in
the dark for 30 min. For supershift assays 1 mg of p65 or p50
antibody (gift of the NCI Preclinical Repository) was added to the
nuclear extract prior to DNA binding and incubated for 30 min at
4uC. Orange loading dye was added to samples which were loaded
on pre-run 5% TBE gels and run at 70 V for 2 h. The gel was
scanned using an Odyssey Infrared Imaging System (LI-COR,
Inc,. Lincoln, NE).
Real-time RT PCR
The RNA from HaCaT and normal keratinocytes treated with
20(OH)D3 or 1,25(OH)2D3 was isolated using Absolutely RNA
Miniprep Kit (Stratagen). Reverse transcription (100 ng/reaction)
was performed with Transcriptor First Strand cDNA Synthesis Kit
(Roche). Real-time PCR was performed using cDNA diluted 10-
fold in sterile water and a TaqMan PCR Master Mix (n=3).
Reactions were performed at 50 uC for 2 min, 95 uC for 10 min
and than 50 cycles of 95 uC for 15 s, 60 uC for 1 min). The
primers and probes were designed with universal probe library
(Roche): IkBa primers (left: GTCAAGGAGCTGCAGGAGAT
and right: GATGGCCAAGTGCAGGAA), probe #38; NFkB1
primers (left: ACCCTGACCTTGCCTATTTG and right:
AGCTCTTTTTCCCGATCTCC), probe #39; and RelA prim-
ers (left: CGGGATGGCTTCTATGAGG and right:
CTCCAGGTCCCGCTTCTT), probe #47; VDR primers (left:
CTTACCTGCCCCCTGCTC and right AGGGTCAGG-
CAGGGAAGT), probe #58. The data was collected on a Roche
Light Cycler 480. The amounts of product were compared to
Cyclophilin B using a comparative CT method.
Statistical analysis
Data are presented as means6STDEV and were analyzed with
Student’s t-test (for 2 groups) and one-way Anova with appropriate
post-hoc test (for more than 2 groups) using Excel (Microsoft) and
Prism 4.00 (GraphPad Software, San Diego), respectively.
Statistically significant differences are denoted with asterisks:
*P,0.05, **P,0.001.
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